| Literature DB >> 27247928 |
Farimah Beheshti1, Majid Khazaei2, Mahmoud Hosseini3.
Abstract
Nigella sativa (NS) (Ranunculaceae family) is generally utilized as a therapeutic plant all over the world. The seeds of the plant have a long history of use in different frameworks of medicines and food. In Islamic literature, it is considered as one of the greatest forms of therapeutics. It has been widely used to treat nervous system diseases such as memory impairment, epilepsy, neurotoxicity, pain, etc. Additionally, this is uncovered that the majority of therapeutic properties of this plant are due to the presence of thymoquinone (TQ) which is a major bioactive component of the essential oil. Pharmacological studies have been done to evaluate the effects of NS on the central nervous system (CNS). The present review is an effort to provide a detailed scientific literature survey about pharmacological activities of the plant on nervous system. Our literature review showed that NS and its components can be considered as promising agents in the treatment of nervous system disorders.Entities:
Keywords: Central nervous system; Neuropharmacological effects; Nigella sativa; Thymoquinone
Year: 2016 PMID: 27247928 PMCID: PMC4884225
Source DB: PubMed Journal: Avicenna J Phytomed ISSN: 2228-7930
Different effects of NS on neurotoxicty and neurodegeneration in experimental studies
|
|
|
|
|
|
|---|---|---|---|---|
|
| 1.642 mg of in a 1 ml of solution made of DMSO | Embryos Wistar rat brains | Antioxidative effects against amyloid beta | Alhebshi, et al., 2013 |
|
| 100 nM | Synaptic toxicity of α-synuclein in rats | Inhibition of synaptic toxicity | Alhebshi, et al., 2013 |
|
| 2.5, 25, and 250 μg/mL and two time points (15 and 60 min) / two time focuces (15 and 60 min) | beta-amyloid toxcification | Protection against beta-amyloid protein intoxication | El-Naggar, et al., 2010 |
|
| 0.1 and 1 µM pretreatment | Amyloid-beta -induced apoptosis of CGNs | Prevention of neurotoxicity and amyloid-beta -induced apoptosis | Ismail, et al., 2013 |
|
| NS extract (15.62–250 μg/ml) and TQ (1.17–150 μM) p | PC12 cytotoxicity | protect PC12 cells against cytotoxic agents | Mousavi, et al., 2010 |
|
| in vitro study 10, 15, 25 and 35 μ M | Ethanol-induced neuronal apoptosis, in vitro study, in rat cortical neuron | protective role against ethanol-induced neuronal apoptosis in primary rat cortical neurons | Ullah, et al., 2012 |
|
| i.p. administration from day 1 till day 50 | CR-EAE Mice | Antiaoxidative effects | Mohamed, et al., 2009 |
|
| 40 mg/kg/day for two months | Aged MOB and PC in female albino rat | Neuroprotective | Eltony, et al., 2014 |
|
| 5 and/or 10 mg/Kg three times at an interval of 24 h. | 6-hydroxydopamine (6-OHDA)-lesioned rats | Sedaghat, et al., 2014 | |
|
| 400mg/kg body weight) once a day orally/ for 30 days started just after trauma | In the trauma sciatic nerve of rats induced by placing an aneurysm clip on the left leg | Jaavanbakht, et al., 2013 | |
|
| NS 400 mg/kg body weight) TQ (50 mg/kg body weight) once a day orally by using intra gastric intubation/ for 12 weeks | Toluene-induced neurodegeneration in the rat hippocampus | Reduction of neurodegeneration | Kanter 2008 |
|
| 400 mg/ kg, orally/ for seven days | Middle cerebral artery occluded (MCAO) rats | Antioxidative effects by reduced the oxidative stress parameters | Akhtar, et al., 2012 |
|
| 400 mg/kg, per orally for seven days | MCAO rats | Antiaoxidative effects | Akhtar, et al., 2013 |
|
| (5 mg/kg/day p.o.) 5 days before ischemia and continued during the reperfusion time | Transient forebrain ischemia in the rat hippocampus | Antioxidative effects by reduced the oxidative stress parameters | Al-Majed, et al., 2006 |
|
| adminstration of 0.01, 0.1, 1, 10 µm on day 8 i.v./ for 4 days | Parkinson’s disease model involving rotenone and neuroinflammatory mechanisms | Anti-dopaminergic effects | Radad, etal., 2009 |
|
| 0.2 ml/kg, intraperitoneally | SAH rats | Antioxidative effects by reduced the oxidative stress parameters | Ersahin, et al., 2011 |
|
| 10 and 50mg/kg were used during surgery through IP/ during surgery | Neuronal damage induced by Global cerebral ischemia reperfusion | Hobbenaghi, et al., 2014 |
A summary of all the experiments done on NS and drug tolerance and withdrawal
|
|
|
|
|
|
|---|---|---|---|---|
|
| 4 mL/kg, p.o. | Tramadol-dependent mice | Blockade of NO overproduction | Abdel-Zaher, et al., 2011 |
|
| 500 mg | Patients with opioid dependence | Sangi, et al., 2008 | |
|
| 200 and 400 mg/kg, i.p./ 60 min before morphine administration on the conditioning days and 60 min before the post-conditioning phase | Morphine-induced CPP, rats | Interaction of NS and glutamatergic system | Anvari, et al., 2012 |
A summery of all the experiments regarding the effects of NS on learning and memory impairment
|
|
|
|
|
|
|---|---|---|---|---|
|
| Oral administration | Memory impairment in diabetic animals | Jalali, et al., 2009 | |
|
| 200 or 400 mg/kg of NS (intraperitoneally)/ for two weeks | Scopolamine-induced deficit memory | Redusction inacetylcholinestrase activity | Hosseini et al., 2015 |
|
| 1 ml/kg, p.o. | Scopolamine-induced deficit of spatial and nonspatial working memory impairment in rats | Antioxidant and anti-inflammatory effects | El-Marasy, et al., 2012 |
|
| 100,200 and 400 mg/kg in drinking water/ 8 weeks | PTU- induced learning and memory impairment | Antioxidant | Beheshti, et al., 2014s |
|
| 100,200 and 400 mg/kg in drinking water/ 8 weeks | Rats | Beheshti, et al., 2014 | |
|
| 200 and 400 mg/kg, i.p/ before PTZ injection for 5 consecutive days | Rats | Antioxidant | Vafaee, et al. 2015 |
|
| 500 mg NS capsule twice daily for nine weeks | Elderly volunteers | Bin Sayeed, et al., 2013 | |
|
| 200 or 400 mg/kg | Scopolamine-induced spatial memory deficits in rats | Inhibition of AChE activity | Hosseini, et al., 2014 |
|
| Force-fed daily at the dose of 6.0 μL/100 g body weight | Twelve Sprague Dawley rats | Antioxidant and neuroprotective effects | Sahak, et al., 2013 |
|
| long-term administration | Rat | Increase in 5-HT levels in brain | Perveen, et al., 2008 |
Asummery of all the experiments done on NS and epilepsy
| Drug |
|
|
| aqueous seed extract of NS | Oral administration | Jalali, et al., 2009 |
| TQ | 200 or 400 mg/kg of NS (intraperitoneally)/ for two weeks 1 ml/kg, p.o. | El-Marasy, et al., 2012 |
| TQ | 100,200 and 400 mg/kg in drinking water/ 8 weeks | Beheshti, et al., 2014s |
| aqueous extract of NS | 100,200 and 400 mg/kg in drinking water/ 8 weeks | Vafaee, et al. 2015 |
| TQ | 200 and 400 mg/kg, i.p/ before PTZ injection for 5 consecutive days | Bin Sayeed, et al., 2013 |
| NSO | Force-fed daily at the dose of 6.0 μL/100 g body weight | Sahak, et al., 2013 |
A summary of all the experiments done regarding the effects of NS on pain
|
|
|
|
|
|
|---|---|---|---|---|
|
| 50 mg/kg | Male albino mice | Bashir, et al., 2010 | |
|
| 1.25, 2.5, and 5 mg/kg, i. p./ once a day for 14 days | Neuropathic pain of rats with chronic constrictive injury of the sciatic nerve | Amin, et al., 2014 | |
|
| p.o. administration of NSO (50-400 mg/kg), The systemic administration (2.5-10 mg/kg, p.o. and 1-6 mg/kg, i.p.) and the i.c.v. injection (1-4 microgram/mouse) of TQ | Mice | Indirect activation of the supraspinal mu - and kappa-opioid receptor subtypes | Abdel-Fattah, et al., 2000 |
|
| 100, 200 and 400 micro L/kg i.p. injection | Carrageenan-induced paw oedema in rats | Mechanism(s) other than opioid receptors | Hajhashemi, et al., 2004 |